What is the dosage of Nabivelol for hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nebivolol Dosage for Hypertension

The recommended dosage of nebivolol for hypertension is 5 mg once daily, which can be titrated up to a maximum of 40 mg daily if needed for blood pressure control. 1

Dosing Guidelines

Nebivolol is a highly selective beta-1 adrenergic receptor blocker with unique vasodilatory properties mediated through nitric oxide modulation. The FDA-approved dosing regimen for hypertension is as follows:

  • Initial dose: 5 mg once daily (with or without food)
  • Dose titration: Can be increased at 2-week intervals if needed
  • Maximum dose: Up to 40 mg daily
  • Frequency: Once daily dosing is sufficient; more frequent dosing provides no additional benefit 1

Special Populations

Renal Impairment

  • Severe renal impairment (CrCl <30 mL/min): Start with 2.5 mg once daily and titrate slowly if needed
  • Dialysis patients: Not studied, use with caution 1

Hepatic Impairment

  • Moderate hepatic impairment: Start with 2.5 mg once daily and titrate slowly if needed
  • Severe hepatic impairment: Not recommended 1

Elderly Patients

  • No dose adjustment necessary for elderly patients 1

CYP2D6 Poor Metabolizers

  • No dose adjustments necessary; clinical effects and safety profiles are similar to extensive metabolizers 1

Efficacy and Comparison to Other Antihypertensives

Nebivolol effectively reduces blood pressure, with its antihypertensive effect becoming apparent within two weeks of treatment and maintaining efficacy throughout the 24-hour dosing interval 2. Studies have shown that:

  • Nebivolol 5 mg daily reduces resting diastolic blood pressure as effectively as standard therapeutic dosages of atenolol, metoprolol, lisinopril, and nifedipine 3
  • It is superior to other beta-blockers and diuretics for systolic blood pressure management 4
  • For diastolic blood pressure control, nebivolol is more efficient than other beta-blockers, angiotensin receptor blockers, diuretics, and calcium channel blockers 4

Unique Properties and Benefits

Nebivolol has several advantages over traditional beta-blockers:

  • Vasodilatory effects: Induces vasodilation through stimulation of the endothelial nitric oxide/L-arginine pathway 5
  • Metabolic neutrality: Does not significantly influence glucose or plasma lipid metabolism 2, 3
  • Favorable side effect profile: Less likely to cause sexual dysfunction, fatigue, and metabolic effects compared to older beta-blockers 2
  • Beneficial in comorbidities: Demonstrated benefits in patients with heart failure 2

Common Side Effects and Precautions

Common adverse effects include:

  • Hypotension
  • Bradycardia
  • Dizziness
  • Fatigue 2

Contraindications

Nebivolol is contraindicated in patients with:

  • Severe bradycardia
  • AV block of second or third degree
  • Cardiogenic shock
  • Decompensated heart failure
  • Sick sinus syndrome (unless a permanent pacemaker is in place) 2

Important Clinical Considerations

  • Avoid abrupt cessation of nebivolol as this can lead to rebound hypertension 6
  • Nebivolol may be particularly beneficial in patients with diabetes mellitus due to its favorable effect on glycemic control 2
  • The drug undergoes extensive hepatic metabolism through the cytochrome P450 2D6 system, so be cautious when co-administering with drugs that affect this enzyme 5

Nebivolol represents a modern beta-blocker option with vasodilatory properties that make it an effective choice for hypertension management while potentially offering advantages over traditional beta-blockers in terms of metabolic effects and tolerability.

References

Guideline

Antihypertensive Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.